Results 201 to 210 of about 8,509,826 (346)

Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?

, 1998
R.T.D. Oliver
openalex   +1 more source

Investigation of a broad‐spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient–drug interactions

British Journal of Clinical Pharmacology, EarlyView.
Aims Daily broad‐spectrum micronutrients are being used by the general public and formulations are receiving research interest in mental health settings. Despite concerns about combining medicines and broad‐spectrum micronutrients in mental health care, there have not been any formal evaluations of potential interactions.
Bess M. Kew, Matthew P. Doogue, Richard McNeill, Mei Zhang, Julia J. Rucklidge, Christopher M. Frampton, Roger T. Mulder, Ben Beaglehole   +7 more
wiley   +1 more source

Placebo Response Rates in Acupuncture Therapy Trials for Functional Dyspepsia: A Systematic Review and Meta-Analysis. [PDF]

J Clin Gastroenterol, 2022
Liu J, Song G, Huang Y, Lv C, Wang Y, Wu D, Sun C, Jing M, Yu Y.   +8 more
europepmc   +1 more source

The placebo response: friend or foe?

, 1995
A. Wan Po, Jan Pegg, S. Louis Bridges
openalex   +1 more source

A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status [PDF]

, 2002
Elvina Karyadi, Clive E. West, Werner Schultink, Ronald H. H. Nelwan, Rainer Gross, Zulkifli Amin, W.M.V. Dolmans, H. Schlebusch, Jos WM van der Meer   +8 more
openalex   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients

, 2000
Oh‐Young Lee, Julie Munakata, Bruce D. Naliboff, Lin Chang, Emeran A. Mayer   +4 more
openalex   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Dipeptidyl peptidase‐1 (DPP‐1) inhibitors have been studied for the treatment of neutrophil‐mediated inflammatory diseases including bronchiectasis, bronchial asthma and cystic fibrosis. This study evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of DPP‐1 inhibitor HSK31858 in healthy Chinese volunteers.
Yuhao Wang, Chao Yu, Mengyue Hu, Lu Wang, Meixia Chen, Hanmo Liu, Nan Wu, Jie Hou   +7 more
wiley   +1 more source

The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder. [PDF]

Br J Clin Pharmacol, 2022
Nasser A, Gomeni R, Wang Z, Hull JT, Busse GD, Melyan Z, Fava M, O'Neal W, Rubin J.   +8 more
europepmc   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.
Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano   +4 more
wiley   +1 more source